Anticancer research最新文献

{"title":"Impact of Radiographical Consolidation of Tumor Size of Part-solid Adenocarcinomas on Survival - A Propensity Score-matching Analysis.","authors":"Haruaki Hino, Natsumi Maru, Takahiro Utsumi, Hiroshi Matsui, Yohei Taniguchi, Tomohito Saito, Katsuyasu Kouda, Tomohiro Murakawa","doi":"10.21873/anticanres.17739","DOIUrl":"https://doi.org/10.21873/anticanres.17739","url":null,"abstract":"<p><strong>Background/aim: </strong>Recent evidence indicates that the radiographical consolidation tumor size of part-solid adenocarcinomas does not have prognostic value unlike that of pure-solid adenocarcinomas. We analyzed the impact of consolidation tumor size on postoperative survival in patients with part-solid adenocarcinoma.</p><p><strong>Patients and methods: </strong>This retrospective study analyzed data of 375 patients with part-solid adenocarcinomas who underwent surgery at our Institute between 2006 and 2021. The consolidation-to-tumor ratio (CTR) was determined using preoperative computed tomography and the patients were grouped into groups with low (0-≤0.5, n=187) or high (>0.5 to <1, n=188) CTR. Clinical characteristics and survival were analyzed using propensity score-matching for radiographical consolidation tumor size.</p><p><strong>Results: </strong>A larger radiographical consolidation tumor size significantly correlated with higher CTR (r²=0.56, <i>p</i><0.0001) and larger pathological invasive size (r²=0.41, <i>p</i><0.0001). Male sex and high radiographical consolidation tumor size were significant negative risk factors for overall survival in the unmatched cohort. The 5-year overall survival rates in the low- and high-CTR groups were 95.2% <i>versus</i> 85.2% (<i>p</i>=0.008) in the unmatched cohort, and 93.0% <i>versus</i> 83.2% (<i>p</i>=0.10) in the matched cohort. Competing-risk analysis showed 5-year cumulative incidence of cancer-specific death were 0% [95% confidence interval (CI)=not estimable] and 5.57% (95% CI=2.10-11.70%) in the low- and high-CTR groups, respectively (<i>p</i>=0.01), in contrast, the corresponding rates of non-cancer-related death were 4.72% (95% CI=1.40-11.10%) and 9.44% (95% CI=4.50-16.50%), respectively (<i>p</i>=0.18). These results indicate that survival of patients with consolidation-dominant part-solid adenocarcinoma is poor due to a higher rate of lung cancer death.</p><p><strong>Conclusion: </strong>The radiographical consolidation tumor size may affect overall survival and possibly reflect tumor growth activity, being consistent with 8^th edition of the TNM classification in that larger consolidation tumor size significantly correlates with poor survival.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3795-3807"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.","authors":"Calogero Cipolla, Vittorio Gebbia, Vincenzo DI Stefano, Christian Messina, Daniela Sambataro, Filippo Brighina, Chiara Mesi, Martina Greco, Andrea Cortigiani, Maria Rosaria Valerio","doi":"10.21873/anticanres.17761","DOIUrl":"https://doi.org/10.21873/anticanres.17761","url":null,"abstract":"<p><strong>Background/aim: </strong>Opsoclonus-myoclonus syndrome (OMS) is rarely associated with breast cancer. This paraneoplastic syndrome poses significant diagnostic and therapeutic challenges for physicians.</p><p><strong>Case report: </strong>This article discusses a case of a 58-year-old Caucasian woman with complex neurological symptoms identified as paraneoplastic OMS due to non-metastatic breast carcinoma. This autoimmune disorder is associated with onco-neural autoantibodies, precisely type II anti-Ri nuclear antibody (ANNA-2), which targets the intracellular Ri antigen (Ri-PNS) and cross-reacts with two neuron-specific antigens. A multidisciplinary approach involving neurologists played a crucial role in case management. Left breast biopsy revealed a poorly differentiated ductal infiltrating carcinoma of the left breast, with 95% positive estrogen receptors, 12% positive progesterone receptors, HER-2 1+, FISH not amplified, and Ki67 at 50%. The patient underwent quadrant surgery for breast cancer and received hormonal therapy with anastrozole. To date, the patient is cancer-free; however, OMS persists. Neurological treatment did not yield significant or durable results. In conclusion, the medical literature on OMS in patients with breast cancer is fragmentary.</p><p><strong>Conclusion: </strong>This report illustrates the complexity of managing breast cancer patients with OMS and reinforces the critical need for a multidisciplinary approach.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"4037-4045"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.","authors":"Hidenori Suzuki, Hiroya Taniguchi, Yoshitaka Inaba, Hiroyuki Tachibana, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai","doi":"10.21873/anticanres.17746","DOIUrl":"https://doi.org/10.21873/anticanres.17746","url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.</p><p><strong>Patients and methods: </strong>Twenty-three patients with olfactory neuroblastoma who underwent initial definitive treatment from 1998 to 2023 were enrolled in this retrospective study.</p><p><strong>Results: </strong>Patients who underwent surgery were significantly associated with longer local recurrence-free survival from the initial definitive treatment compared to those who underwent radiotherapy. Among 18 patients with residual disease or first recurrence, those with distant metastasis related significantly with shorter overall survival from the diagnosis day of residual disease/first recurrence. Among 11 patients with unresectable multi-recurrent olfactory neuroblastoma, the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT.</p><p><strong>Conclusion: </strong>PRRT was associated with improved survival in patients with unresectable multi-recurrent olfactory neuroblastoma.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3877-3884"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Antitumor Efficacy and Toxicity Profile of SCC5, An Ag(I) <i>N</i>-Heterocyclic Carbene Complex, Relative to Platinum-based Chemotherapeutics.","authors":"Joseph A Bauer, Annette M Sysel, Michael J Dunphy","doi":"10.21873/anticanres.17727","DOIUrl":"https://doi.org/10.21873/anticanres.17727","url":null,"abstract":"<p><strong>Background/aim: </strong>Platinum-based chemotherapeutics remain the standard of care for many solid tumors; however, they have dose-limiting toxicities. Silver(I) <i>N</i>-heterocyclic carbene complexes represent a novel class of metallodrugs with potential anticancer activity and improved tolerability. This study evaluated SCC5, a silver(I) acetate complex derived from 1,3-dimethyl-4,5-dichloroimidazole-2-ylidene, across a panel of human cancer cell lines and <i>in vivo</i> toxicity models. Mechanistic analysis of apoptosis was also performed using caspase-8 immunoblotting.</p><p><strong>Materials and methods: </strong>Eight human cancer cell lines (melanoma, colon, renal, bladder, ovarian, and prostate) were treated with SCC5 and three FDA-approved platinum drugs (cisplatin, carboplatin, oxaliplatin). Antiproliferative activity was measured using the sulforhodamine B assay. <i>In vivo</i> toxicity was assessed in CD-1 mice receiving escalating intraperitoneal doses (10-50 mg/kg), with survival monitored over 21 days. Caspase-8 was analyzed by western blotting in SCC5-treated HT-29 cells.</p><p><strong>Results: </strong>SCC5 exhibited half-maximal inhibitory doses ranging from 10 to 30 μM, comparable to carboplatin and was slightly less potent than cisplatin and oxaliplatin. However, SCC5 demonstrated superior safety, with 100% survival at doses that were lethal to platinum compounds, supporting its more favorable therapeutic index. Western blot analysis revealed dose- and time-dependent loss of caspase-8 expression following SCC5 treatment, suggesting activation of apoptosis-related pathways.</p><p><strong>Conclusion: </strong>SCC5 maintains broad-spectrum antiproliferative activity with markedly improved <i>in vivo</i> tolerability compared to platinum drugs. These findings support continued preclinical development of SCC5 as a novel silver-based chemotherapeutic.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3629-3637"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The UALCAN and GEPIA Analyses of the TCGA Database Show a Strong Association Between Increased Expression of <i>Stathmin 1</i> in Adrenocortical Carcinoma Tissues and Patient Survival.","authors":"Shin-Nosuke Yamashita, Yoshiatsu Tanaka, Shajedul Islam, Takao Kitagawa, Kazuhiro Tokuda, Durga Paudel, Sarita Giri, Tohru Ohta, Fumiya Harada, Hiroki Nagayasu, Yasuhiro Kuramitsu","doi":"10.21873/anticanres.17749","DOIUrl":"https://doi.org/10.21873/anticanres.17749","url":null,"abstract":"<p><strong>Background/aim: </strong>Adrenocortical carcinoma (ACC) arises from the adrenal cortex. This cancer is characterized by a very low incidence, poor prognosis and high mortality rate. Because early detection is extremely difficult and no effective treatment has been established, the five-year survival rate is very low. Therefore, there is an urgent need to identify biomarkers and therapeutic target molecules that can serve as early detection and prognostic factors. Stathmin 1 is a ubiquitously expressed 19 kDa cytosolic phosphoprotein, which induces microtubule depolymerization and regulates microtubule-dependent processes such as cell division and motility. Its over-expression has been linked to cell migration and invasion in sarcoma, malignant glioma, gastric cancer, colorectal cancer, and non-small cell lung cancer. However, the clinicopathological involvement of stathmin 1 in ACC, has not yet been reported.</p><p><strong>Materials and methods: </strong>The GEPIA and UALCAN platforms were used to analyze <i>stathmin 1</i> mRNA expression and its association with survival in patients with ACC using TCGA data.</p><p><strong>Results: </strong>TCGA analysis showed that the expression of <i>stathmin 1</i> was significantly increased in ACC tissues, and patients with increased expression of <i>stathmin 1</i> in cancer tissues had a significantly shorter survival time.</p><p><strong>Conclusion: </strong><i>Stathmin 1</i> is highly expressed in ACC tissues and inversely correlated with patient prognosis, suggesting it may be a potential prognostic biomarker for patients with ACC. Furthermore, the GEPIA and UALCAN platforms proved to be highly effective in investigating the correlation between the expression levels of <i>stathmin 1</i> in ACC tissues and the survival time of patients using the TCGA database.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3913-3920"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TGF-B-induced Cancer-associated Fibroblast Activation Promotes Tumor Progression In Oral Squamous Cell Carcinoma Mouse Model.","authors":"Junya Hirota, Daisuke Takeda, Yasuaki Sadakane, Yudai Matsuzoe, Yoshiaki Tadokoro, Aki Murakami, Nanae Yatagai, Izumi Saito, Masaya Akashi, Takumi Hasegawa","doi":"10.21873/anticanres.17731","DOIUrl":"https://doi.org/10.21873/anticanres.17731","url":null,"abstract":"<p><strong>Background/aim: </strong>Oral squamous cell carcinoma (OSCC) is a common malignancy with a poor prognosis, partly due to interactions within the tumor microenvironment. Cancer-associated fibroblasts (CAFs), key stromal components, promote tumor progression by enhancing cancer cell migration, angiogenesis, and extracellular matrix remodeling. Transforming growth factor-beta (TGF-β) is known to induce CAF differentiation from normal fibroblasts (NFs), but its functional contribution in OSCC remains to be fully elucidated. This study explored the role of TGF-β in inducing the transition of NFs into CAFs and its impact on progression of OSCC.</p><p><strong>Materials and methods: </strong><i>In vitro</i>, NFs were treated with TGF-β, and CAF induction was assessed by evaluating the expression of the CAF marker α-smooth muscle actin (α-SMA) using quantitative real-time PCR and fluorescent immunostaining. OSCC cell migration was analyzed using a scratch assay. <i>In vivo</i>, TGF-β-treated or untreated NFs were co-injected with OSCC cells. The tumor size and VEGF, MMP2, and MMP9 expression were analyzed <i>via</i> quantitative real-time PCR and immunohistochemistry.</p><p><strong>Results: </strong><i>In vitro</i>, TGF-β-treated NFs exhibited significantly increased α-SMA expression and enhanced the OSCC migratory ability. <i>In vivo</i>, the TGF-β-treated group demonstrated a marked increase in tumor growth and up-regulated expression of VEGF, MMP2, and MMP9 compared to the untreated group.</p><p><strong>Conclusion: </strong>These findings suggest that TGF-β induces CAF differentiation and facilitates tumor progression by promoting angiogenesis and extracellular matrix degradation. This study highlights the potential of targeting TGF-β as a therapeutic strategy and underscores the need for novel approaches to counteract the tumor-promoting effects of CAFs.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3687-3700"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy.","authors":"Takafumi Fukui, Suya Hori, Yukihisa Hatakeyama, Tatsunori Kiriu, Kanoko Matsumura, Nanako Miwa, Masahiro Katsurada, Keiko Okuno, Sho Yoshimura, Motoko Tachihara","doi":"10.21873/anticanres.17745","DOIUrl":"https://doi.org/10.21873/anticanres.17745","url":null,"abstract":"<p><strong>Background: </strong>The optimal treatment for advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 1-49% remains unknown. Further stratification by PD-L1 TPS may lead to optimization of treatment.</p><p><strong>Patients and methods: </strong>We conducted a multicenter, retrospective, observational study to compare nivolumab and ipilimumab with/without chemotherapy (dual-therapy group) and chemotherapy with a single-agent immune checkpoint inhibitor (ICI) (single-therapy group) as the first-line therapy for advanced NSCLC with a PD-L1 TPS of 1-49%. The primary endpoint was overall survival in the propensity score-matched population.</p><p><strong>Results: </strong>A total of 139 patients were enrolled; 113 in the single- (81.3%) and 26 in the dual- (18.7%) therapy groups. In the population with PD-L1 TPS of 1-20%, after propensity score-matching was performed, the median overall survival was 12.0 months for the single-therapy group, but was not reached for the dual-therapy group (<i>p</i>=0.022). The median progression-free survival was 6.9 and 11.5 months, respectively (<i>p</i>=0.02). In the population with PD-L1 TPS of 21-49%, after propensity score-matching, the median overall survival was not reached for the single-therapy group, but was 9.0 months for the dual-therapy group (<i>p</i>=0.04), whilst corresponding median progression-free survival was 8.3 and 4.1 months (<i>p</i>=0.087).</p><p><strong>Conclusion: </strong>The results of this study suggest that in patients with NSCLC, the optimal treatment regimen may differ between those with PD-L1 TPS of 1-20% and 21-49%; moreover, nivolumab and ipilimumab-based therapy may be more effective than chemotherapy with a single-agent ICI for treating advanced NSCLC with ultra-low PD-L1 expression, particularly in those with a PD-L1 TPS of 1-20%.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3859-3875"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Fentanyl and Remifentanil on Immune Response in Breast Cancer Patients Post-surgery.","authors":"Grigorios Lyronis, Eleni Efraimidou, Maria-Eleni Zachou, Antigoni Kaprana, Erasmia Xanthopoulou, Alexandra Giatromanolaki, Michael I Koukourakis, Pelagia Chloropoulou","doi":"10.21873/anticanres.17736","DOIUrl":"10.21873/anticanres.17736","url":null,"abstract":"<p><strong>Background/aim: </strong>The perioperative period may influence immune function in cancer patients, with anesthetic agents potentially contributing to immunosuppression. This study evaluated the differential impact of fentanyl and remifentanil on immune cell populations in breast cancer (BCa) patients undergoing surgery.</p><p><strong>Patients and methods: </strong>Thirty patients with histologically confirmed BCa who were treated with modified radical mastectomy or breast-conserving surgery followed by radiotherapy were included in the study. Anesthesia was administered using either fentanyl (n=12) or remifentanil (n=18). White blood cell (WBC) and lymphocyte (LC) counts were recorded before and 24 h after surgery. Peripheral blood mononuclear cells were analyzed for T-cell subpopulations using flow cytometry.</p><p><strong>Results: </strong>WBC counts increased from a median of 7,025/μl before to 10,065/μl after surgery (<i>p</i><0.0001), whilst LC counts were reduced from a median value of 1,785 to 1,090 (<i>p</i>=0.0002). The median duration of anesthesia was 212 min. Patients who received remifentanil for a shorter anesthesia period (<212 min) experienced a marginal non-significant degree of leukocytosis (<i>p</i>=0.07), while no lymphopenia was evident (<i>p</i>=0.38). In contrast, longer remifentanil exposure significantly induced significant leukocytosis (<i>p</i>=0.01) and lymphopenia (<i>p</i>=0.009), similar to fentanyl. There were no significant differences between fentanyl and remifentanil in their effects on CD4+, CD8+, or CD4+/CD25+/FOXP3+ T-cell populations. Notably, the percentage of CD4+ T-cells was positively correlated with the duration of anesthesia (<i>p</i>=0.002, r=0.53).</p><p><strong>Conclusion: </strong>Optimizing analgesic selection and anesthesia duration may play a crucial role in minimizing immunosuppressive perioperative stress in patients undergoing BCa surgery. Remifentanil combined with shorter anesthesia exposure appears to mitigate immune suppression, suggesting a potential strategy to preserve immune competence during oncologic surgery.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3761-3771"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Clinical Impact of Severe Periodontitis in Patients With Gastric Cancer.","authors":"Kazuya Takabatake, Takeshi Kubota, Hiroyuki Inoue, Keiji Nishibeppu, Jun Kiuchi, Hidemasa Kubo, Taisuke Imamura, Kenji Nanishi, Hiroki Shimizu, Tomohiro Arita, Yusuke Yamamoto, Hirotaka Konishi, Ryo Morimura, Hitoshi Fujiwara, Atsushi Shiozaki","doi":"10.21873/anticanres.17747","DOIUrl":"https://doi.org/10.21873/anticanres.17747","url":null,"abstract":"<p><strong>Background/aim: </strong>A potential link between periodontitis and the development of gastric cancer (GC) has been reported. However, its prevalence and impact on patients with GC remain unclear. This study investigated the association between periodontitis severity and clinical parameters, including <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection and endoscopic findings, in patients with GC undergoing gastrectomy.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included 145 patients who underwent curative gastrectomy with perioperative oral care (2020-2023). Periodontal status was assessed using pocket probing depth (PPD), bone resorption, and remaining teeth. Severe periodontitis was defined as PPD ≥6 mm, horizontal bone resorption ≥33%, furcation involvement (class II/III), vertical bone resorption ≥3 mm, or <20 remaining teeth. Clinical variables were compared between no/mild and severe periodontitis groups.</p><p><strong>Results: </strong>The median number of remaining teeth was 24; 65.5% of patients had ≥20 teeth. PPD ≥6 mm was observed in 29.4%, and gingival bleeding in 71.3%. Severe periodontitis was diagnosed in 64.8% of patients and was associated with older age (≥70 years; 70% <i>vs.</i> 39%, <i>p</i><0.001), higher C-reactive protein (≥1.0 mg/dl; 10% <i>vs.</i> 0%, <i>p</i>=0.002), and lower albumin (<3.5 g/dl; 14% <i>vs.</i> 2%, <i>p</i>=0.009) levels. It was more common in patients with differentiated adenocarcinoma (<i>p</i>=0.005) and lymphatic invasion (<i>p</i>=0.006) but not significantly associated with <i>H. pylori</i> infection or endoscopic findings.</p><p><strong>Conclusion: </strong>Patients with GC have a high prevalence of severe periodontitis, linked to systemic inflammation, poor nutrition, and aggressive tumor characteristics, emphasizing the need for integrated periodontal care.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3885-3894"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab.","authors":"Fumihiko Sato, Takeharu Ono, Akira Hiraki, Tsunehiro Oka, Toshiyuki Mitsuhashi, Masayasu Naito, Mioko Fukahori, Shintaro Sueyoshi, Itaru Mizobe, Masahiro Seki, Kiminobu Sato, Toshihiko Kawaguchi, Hisaichiro Tanaka, Takashi Kurita, Shun-Ichi Chitose, Hirohito Umeno","doi":"10.21873/anticanres.17757","DOIUrl":"https://doi.org/10.21873/anticanres.17757","url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic inflammation, immunity, and nutrition-based prognostic indices (SIINBPIs) have been associated with cancer prognosis. This study evaluated their prognostic relevance in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with nivolumab.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 103 R/M HNSCC patients who received nivolumab. Pretreatment blood tests were used to calculate SIINBPIs including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), high-sensitivity modified Glasgow Prognostic Score (HS-mGPS), and the C-reactive protein-albumin-lymphocyte (CALLY) index.</p><p><strong>Results: </strong>The CALLY index and performance status were identified as independent prognostic factors for overall survival (OS). Patients with a high CALLY index had better performance status and were more likely to receive subsequent chemotherapy. The CALLY index showed superior prognostic performance over other SIINBPIs.</p><p><strong>Conclusion: </strong>The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3993-4004"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}